RIKEN OSC to purchase CLC bio's high-throughput sequencing analysis solution

Today, RIKEN and CLC bio Japan announced an agreement for the purchase of CLC bio's enterprise platform software by RIKEN Omics Science Center (OSC). CLC bio's high-throughput sequence analysis infrastructure will empower both OSC's scientists and OSC's Genome Network Analysis Service (GeNAS) with a user-friendly and fast workflow to efficiently manage and analyze large quantities of genomics data.

“Having such an advanced and world renowned research center choose our enterprise platform emphasizes CLC bio as the global leader in high-throughput sequencing analysis solutions. Furthermore, it establishes CLC bio Japan as the major solution provider in the Japanese sequence analysis market.”

RIKEN OSC Facility Director, Dr. Carsten O. Daub, states, "It is customary for us to develop our own in-house software that is tailor-made to our very specialized needs. However, we were very impressed with the performance and flexibility of CLC bio's software for a wide range of high-throughput sequence analysis projects and decided that it would be faster and more efficient for us to adopt their enterprise platform."

CEO at CLC bio Japan, David Leangen, continues, "Having such an advanced and world renowned research center choose our enterprise platform emphasizes CLC bio as the global leader in high-throughput sequencing analysis solutions. Furthermore, it establishes CLC bio Japan as the major solution provider in the Japanese sequence analysis market."

CEO at CLC bio, Thomas Knudsen, adds, "This agreement accentuates the importance of the Japanese market to CLC bio. To stress our commitment to our operations in Japan, we're already planning further expansions of CLC bio Japan!"

Source RIKEN Omics Science Center and CLC bio Japan